UBS analyst Andrea Alfonso initiated coverage of Idexx Laboratories (IDXX) with a Neutral rating and $720 price target Top-line estimates already sufficiently credit new cytology launches and the customer ramp outside the U.S., the analyst tells investors in a research note. The firm’s survey work suggests mixed adoption for the inVue analyzer but even with conservative inputs, UBS is modeling inVue alone driving 1%-2% annual contribution on top of platforms still growing, suggesting multiple levers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- Idexx Laboratories: Balancing Growth Opportunities and Revenue Challenges in a High-Growth Sector
- INTC, SMCI, UNH: August’s Best and Worst-Performing Stocks
- Idexx Laboratories: A Strong Buy Amidst Veterinary Healthcare Market Resilience
- Idexx Laboratories price target raised to $700 from $510 at Piper Sandler
- QQQ ETF News, 8/6/2025